Toripalimab (TUOYI/LOQTORZI) is Junshi's anti-PD-1 monoclonal antibody, with 13 approved indications in mainland China and marketing approvals in more than 50 countries and regions, including the U.S.
As the Chief Development Officer, I lead the Regulatory Affairs, Project Management, Analytical Sciences, Research and Translational Medicine departments. We are focused on expanding the US approval ...
SHANGHAI, July 21, 2026 (GLOBE NEWSWIRE)-- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe
SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Coherus BioSciences has announced promising results from its ongoing Phase 1 clinical trial of CHS-114, a selective anti-CCR8 antibody, in combination with toripalimab for patients with ...
Coherus BioSciences has launched a randomized Phase 2 study to evaluate the efficacy of casdozokitug (casdozo), an IL-27-antagonistic antibody, combined with toripalimab and bevacizumab for treating ...
Initial results from EXCEED, a phase 1 study of LY4101174, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results